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The gastrointestinal tract is a site of high immune challenge, as it must maintain a deli-
cate balance between tolerating luminal contents and generating an immune response 
toward pathogens. CD4+ T cells are key in mediating the host protective and homeo-
static responses. Yet, CD4+ T cells are also known to be the main drivers of inflammatory 
bowel disease (IBD) when this balance is perturbed. Many subsets of CD4+ T cells have 
been identified as players in perpetuating chronic intestinal inflammation. Over the last 
few decades, understanding of how each subset of Th cells plays a role has dramatically 
increased. Simultaneously, this has allowed development of therapeutic innovation 
targeting specific molecules rather than broad immunosuppressive agents. Here, we 
review the emerging evidence of how each subset functions in promoting and sustaining 
the chronic inflammation that characterizes IBD.
Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, T helper cells, inflammatory cytokines, 
transcription factors
CD4+ T CeLLS iN iNFLAMMATORY BOweL DiSeASe (iBD)
Inflammatory bowel disease is a complex set of diseases that includes Crohn’s disease (CD) 
and ulcerative colitis (UC), each with multiple bacterial, immune, and non-immune cell types 
contributing to inflammation. However, there are a number of lines of evidence that suggest 
that CD4+ T helper cells are major initiators in the disease process. CD4+ T  cells are enriched 
in lesional tissue from patients with CD and UC and blockade or depletion of CD4+ T is effec-
tive in treating patients with IBD. In these studies, CD4+ T cell-depleting and blocking antibod-
ies caused remission from disease in a number of CD and UC patients examined, suggesting a 
prominent role of CD4+ T  cells in propagating disease (1, 2). Interestingly, IBD patients with 
concurrent HIV infection also exhibit a greater incidence of remission as compared to non-HIV 
controls, correlating with decreased total blood CD4+ T cell counts (3, 4). Finally, a number of 
biologics that target CD4+ T  cell differentiation into inflammatory subsets or their byproducts 
(i.e., cytokines) have shown efficacy in treating patients with IBD (5–7). Given the importance 
of CD4+ Th cells in the disease process, this review will focus on how Th cells differentiate in the 
inflamed intestinal tract during IBD and how the Th lineage-specific cytokines and transcription 
factors (TFs) contribute to disease.
Th1 CeLLS
Th1 cells are important for protecting against infectious pathogens. These cells primarily produce 
interferon (IFN)-γ and tumor necrosis factor (TNF) that, respectively, activate macrophages and 
direct cytotoxic CD8+ T cell responses, that in turn promote elimination of intracellular pathogens 
such as viruses and bacteria (8). In IBD, however, Th1 cells accumulate in the intestinal tract of indi-
viduals with CD and are directly associated with disease. Interleukin (IL)-12, which is secreted by 
FiguRe 1 | Critical factors in the differentiation of effector Th cells during 
inflammatory bowel disease (IBD). T helper cells recognize antigen presented 
in the context of major histocompatibility complex II on antigen-presenting 
cells in a T cell receptor-dependent fashion (not shown). In conjunction with 
assorted co-stimulatory signals (i.e., CD80/86–CD28 interaction and others), 
these signals initiate a program of cell division and differentiation. This 
differentiation program can be profoundly influenced based on the cytokines 
present in the environment in which they are initiated. Interleukin (IL)-12 and 
IL-23, cytokines induced during early stages of IBD, play important roles in 
differentiation of interferon (IFN)-γ/tumor necrosis factor (TNF)-producing 
Th1 cells as well as IL-17-producing Th17 cells. However, Th17 cells require 
additional signals including IL-6 and TGF-β for full induction of their 
differentiation. IL-6, in combination with TNF-α and tryptophan metabolites, 
initiates differentiation of protective IL-22-producing Th22 cells. Th1 
differentiation is initiated and stabilized by transcription factors signal 
transducer and activator of transcription (STAT)4 and T-bet while Th17 cells 
require a combination of transcriptional regulators including STAT3, SMAD 
proteins, and RORγt. IL-4, IL-5, and IL-13-secreting Th2 and IL-9-secreting 
Th9 cells require IL-4 and STAT6 for their differentiation. Similar to Th17 cells, 
Th9 cells additionally require TGF-β, SMAD proteins, and a TGF-β/
SMAD-induced transcription factor PU.1 for their development. As a whole, 
the inflammatory mediators produced by Th cells in IBD play a role in the 
maintenance or breaking down gut epithelial barriers or in recruiting unique 
cells types to the intestines that further promote inflammation. Factors in red 
indicate genes involved in Th cell differentiation or function that contain single 
nucleotide polymorphisms that are associated with increased disease 
susceptibility or severity in humans (see Table 2).
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antigen-presenting cells, acts via signal transducer and activator 
of transcription (STAT)4 to promote the differentiation of naïve 
T cells into Th1 cells (9–11). STAT4 also signals activation of the 
TF T-bet, a lineage-defining factor for Th1 differentiation, which 
upregulates the IL-12 receptor, IFN-γ expression, and causes 
further expansion of Th1 cells (Figure 1) (12).
Th1-Associated Cytokines
Interferon-γ
Interferon-γ is the defining cytokine produced by Th1 cells and 
is used almost exclusively to identify Th1  cells in settings of 
disease. During intestinal inflammation, IFN-γ in combination 
with another Th1-associated cytokine, TNF, was proposed to 
drive intestinal epithelial cell beta catenin signaling and limit 
their differentiation and proliferation (13). Despite this proposed 
model, the role of IFN-γ in murine IBD is controversial. Powrie 
et  al. (14) and Ito et  al. (15) both demonstrate that IFN-γ is 
required for disease development in a CD45RBhi RAG adoptive 
transfer model and in a DSS model of IBD (see Table 1), respec-
tively. Nava et al. (13) also observed moderately reduced disease 
in IFN-γ-deficient mice in a DSS model of disease. Loss of IFN-γ 
in these reports correlated with overall reduced inflammation and 
tissue damage as well as reduced type-1-associated chemokine 
expression that would recruit other inflammatory cells to the 
intestinal tract. In contrast to these studies, Simpson et al. (16), 
using a adoptive transfer model of colitis modified from Powrie 
et al. (14), demonstrated that IFN-γ was not required for disease 
in this setting. Furthermore, Muzaki et al. (17) showed that IFN-
γ-deficient mice were in fact more susceptible to DSS-induced 
colitis, suggesting a protective role for IFN-γ. In a TNBS model 
of colitis (Table 1), IFN-γ was neither protective nor required for 
disease (18, 19).
The seemingly contradictory nature of the above studies sug-
gests that other factors may be involved or compensate for the 
loss of IFN-γ in some models. Alternatively, the dependence of 
disease on IFN-γ may be a factor of the exact model system used 
or the differences in gut microbiomes within populations of mice 
across institutes or may be attributable to different mouse strains 
used. However, in human GWAS studies, there is a clear enrich-
ment of SNPs in a CD- and UC-associated risk area comprised 
of several regions up and downstream of the human IFNG gene 
(45, 46). Furthermore, a particular IBD-associated SNP within 
the IFNG gene (rs1861494) is functionally linked with elevated 
IFN-γ expression in IBD patients (Figure 1; Table 2) (47). These 
data suggest at least a possible role of IFN-γ in promoting IBD 
in humans.
Tumor Necrosis Factor
A wide array or both immune (i.e., Th1 cells, Figure 1) and non-
immune cells produce TNF during inflammation that induces 
signaling through two distinct receptors, TNFR1 and TNFR2. 
Similar to IFN-γ, TNF has also been demonstrated to be involved 
in intestinal barrier dysregulation during IBD (13) and has a 
varied role in mouse models of intestinal inflammation. Blockade 
of TNF in mice undergoing TNBS-induced disease, exhibited 
reduced weight loss and inflammation (24). Similarly, Yang et al. 
(25) demonstrated that TNFR1-, TNFR2-, and TNFR1/TNFR2 
double-deficient mice exhibited similarly reduced TNBS-induced 
IBD as compared to control mice, suggesting a non-redundant 
role each receptor in this model. However, these findings were 
challenged by other studies in the TNBS model system where 
Ebach et al. (70) demonstrated that TNFR1-deficient mice had 
exacerbated disease and TNFR2-deficient mice had attenuated 
disease compared to controls, suggesting a protective and exac-
erbating role for each receptor, respectively.
Strikingly similar to the role of IFN-γ in murine IBD, the effect 
of TNF also varies greatly between model systems. Despite the 
protective role of TNF blockade in the TNBS model, TNF blockade 
in oxazolone-treated mice had little effect (24). In addition, Stillie 
and Stadnyk (71) showed that both TNFR1 and TNFR2-deficient 
mice developed significant disease after DSS treatment. Even 
TABLe 1 | Models of Th cell-driven inflammatory bowel disease.
Mouse model Type of model Th-type/s involved Key cytokines/TFs Reference
DSS colitis Chemical Th1 (Acute) IFN-γ, TNF, T-bet (13, 15, 20–22)
Th2 (Chronic) IL-4, IL-13, STAT6, GATA3
Th9 IL-9, PU.1
TNBS colitis Chemical Th1 (Acute) TNF, T-bet (23–30)
Th2 (Chronic) IL-13, GATA3
Th9 (Acute) IL-9, PU.1
Th17 (Acute) IL-17R, SMAD7
Oxazolone Chemical Th2, NK-T IL-4, IL-13 (29, 31–35)
Th9 IL-9, GATA3
Th17 TGF-β, SMAD7
Anti-CD40 Chemical (activating antibody) Th1 IL-12 (36)
Th17 IL-17, IL-23
Citrobacter rodentium Infectious Th1 IFN- γ (37, 38)
Th17 IL-17A, IL-17F
RAG or SCID T cell transfer model Transfer Th1 IFN-γ, STAT4, T-bet (14–16, 23, 39–41)
Th17 IL-23, STAT3, SMAD2
Abcb1an−/− Transgenic Th17 IL-23 (42)
Tcrα−/− Transgenic Th2-like IL-4 (43)
Il10/Il10r−/− Transgenic Th17 IL-17, IL-23 (44)
Th-association was determined by induced expression in a particular model or by mechanistic studies, where cytokines/TFs were manipulated by gene deletion or blocking antibody.
Acute, acute exposure to chemical; Chronic, repeating exposure to chemical; STAT, signal transducer and activator of transcription; IL, interleukin; TNF, tumor necrosis factor;  
IFN, interferon; TFs, transcription factors.
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more surprisingly, Wang et al. (72) reported exacerbated disease 
in DSS-treated TNFR1- and TNFR2-deficient mice as compared 
to controls, suggesting a protective role of TNF signaling during 
murine IBD. In these last experiments, lack of TNF signaling 
resulted in production of another auto-immune-associated 
cytokine, GM-CSF that played a critical role in the exacerbated 
disease phenotype, suggesting a role for compensating cytokines 
in some of these model systems. As a whole, these data indicate 
a need for standardization of model systems and sharing of 
reagents between laboratories to uncover potential discrepancies 
in these studies.
In humans, there are several SNPs in the TNF gene that are 
associated with IBD in a number of populations (Figure  1; 
Table 2). In addition, anti-TNF therapy is currently used in treat-
ment of both CD and UC and is effective in a number of patients. 
Interestingly, while anti-TNF therapy was sufficient for complete 
remission of IBD-related symptoms (5, 6, 73), only ~24–50% 
of patients exhibited mucosal wound healing depending on the 
type of anti-TNF antibody used (74, 75). These data indicate a 
disconnect between tissue damage and what generally makes IBD 
patients feel “sick” (i.e., possibly more systemic effects). While 
both factors are relevant end points, mucosal wound healing is 
potentially more meaningful as these patients may be less likely 
to relapse after ceasing anti-TNF therapy.
Th1-Associated TFs
T-bet
T-bet is required for the differentiation of Th1 cells both in vitro 
and in vivo in the context of IBD. Tbx21-deficient CD4 T cells, 
isolated from BALB/c mice, were unable to induce colitis in a SCID 
adoptive transfer model of IBD. Furthermore, overexpression of 
T-bet in Th cells exacerbated experimental colitis in this same 
model (23). By contrast, a more recent study demonstrates that 
Tbx21-deficient CD4 T cells, this time from C57BL/6 mice, pro-
duced similar pathology as WT CD4 T cells (76). However, while 
Tbx21-deficient cells exhibited a dramatic decrease in IFN-γ-
production, there was a corresponding increase in the proportion 
of cells that produced IL-17 and other Th17-associated cytokines 
in the inflamed intestines. Further mechanistic work demons-
trated that Tbx21-deficient cells had heightened sensitivity to 
IL-23 signaling and increased RORγt expression, a TF associated 
with Th17 differentiation. As a whole, these data demonstrate 
that T-bet plays a pivotal role in Th1 differentiation in murine 
models of IBD, however, in some cases, the loss of Th1 cells is 
compensated for by an increase in pathogenic IL-17-producing 
cells resulting in a similar disease phenotype.
T-bet can also play a protective role in murine IBD. Tbx21-
deficient mice develop more severe colitis than control animals 
after treatment with DSS. This elevated disease is marked by 
enhanced immune cell infiltration into the intestines, ulceration, 
and loss of crypts (77). Interestingly, this disease became a spon-
taneous disease when crossed to Rag2-deficient mice that lack T 
and B cells, suggesting that CD4+ T cells do not drive this disease. 
Instead, Garrett et al. (77) and Powell et al. (78) demonstrated that 
colitis in these mice was induced by exaggerated TNF production 
in dendritic cells (DCs) and elevated numbers of IL-17-producing 
innate lymphoid cells (ILCs) in the intestinal tract that causes a 
microbial breach in the intestinal lining.
Human GWAS studies have identified several SNPs that were 
associated with development of UC and CD (46, 79). Interestingly, 
a number of these SNPs sites were enriched for T-bet binding. 
Although T-bet bound a number of these intergenic regions in 
TABLe 2 | Single nucleotide polymorphisms (SNPs) associated with Th-associated cytokines or transcription factors.
gene SNP Th subset association Population studied Disease type Reference
IL12B rs3212227 Th1  – Caucasian
 – Spanish
Crohn’s disease (CD),  
ulcerative colitis (UC)
(48–50)
rs6887695 Th1  – Spanish CD, UC (49)
rs2288831 Th1  – Korean CD (51)
rs10045431 Th1  – British (Caucasian) CD, UC (52, 53)
rs6871626 Th1  – British (Caucasian) CD, UC (54)
rs6556412 Th1  – British (Caucasian) CD, UC (54)
IFNG rs1861494 Th1  – Caucasian CD, UC (47)
rs7134599 Th1  – British (Caucasian) UC (54)
TNF rs1800629 Th1  – Spanish
 – Portuguese
Inflammatory bowel disease (55, 56)
rs1799964 Th1  – Iranian
 – French Canadian
CD (57, 58)
STAT4 rs7574865 Th1  – Spanish UC (59)
rs925847 Th1  – Korean UC (60)
IL23R rs11805303 Th17  – British (Caucasian) CD, UC (48)
rs11209026 Th17  – Dutch(Caucasian),
 – Hungarian(Caucasian),
 – New Zealanders(Caucasian),
 – British (Caucasian)
 – Spanish
CD, UC (49, 61–64)
rs7517847 Th17  – British (Caucasian)
 – Spanish
CD (49, 65)
rs1004819 Th17  – German/Caucasian CD (50)
rs11465804 Th17  – Mixed CD (52)
STAT3 rs12948909 Th17  – British (Caucasian)
 – German (Caucasian)
UC (53, 66, 67)
rs744166 Th17  – Caucasian CD, UC (67)
JAK2 rs10758669 Th17  – British (Caucasian)
 – Mixed
CD, UC (52–54)
STAT6 rs324015 Th2/Th9  – British (Caucasian) CD (68)
IL4 rs2243250 Th2/Th9  – Iranian CD, UC (69)
rs2243248 Th2/Th9  – Iranian CD, UC (69)
4
Imam et al. Effector T Helper Cells in IBD
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1212
healthy individuals, several of these SNPs lead to reduced T-bet 
binding at these sites and altered gene expression of a number of 
Th1 related factors (IL18RAP and TRIB1) (80). Although both 
IL-18 and IL18RAP have been previously shown to be also associ-
ated with IBD, the role of TRIB1 in this setting is unclear. While 
these data need to be further verified using in vivo models of IBD, it 
might suggest that T-bet serves more of an inflammatory role than a 
protective role in human disease.
Signal Transducer and Activator of Transcription 4
Binding of IL-12, produced by DCs and other innate immune 
cells, to its receptor triggers the phosphorylation of STAT4 which 
then translocates to the nucleus and initiates the transcriptional 
network associated with Th1 differentiation (81, 82). STAT4 binds 
a number of distinct regions within the genome including a num-
ber of key Th1-associated genes [i.e., Ifng and Tbx21 (82, 83)]. 
Given its initiator role, STAT4-deficiency leads to a major 
impairment of Th1 differentiation in  vitro as well as in mouse 
models of IBD (9, 10, 16). In support of these initial findings, 
mice engineered to overexpress STAT4 (STAT4-transgenic mice) 
developed an IBD-like disease after administration of dinitrophe-
nyl-conjugated keyhole limpet hemocyanin that correlated with 
increased numbers of IFN-γ and TNF-producing CD4+ T cells 
in the intestines (84). Interestingly, IFN-γ, a key Th1-associated 
gene downstream of STAT4 signaling, was not required for 
disease in an adoptive transfer model of IBD (16). These data 
suggest that although STAT4 is critical for Th1 differentiation 
and disease development in murine IBD, it may promote disease 
IFN-γ-independent manner.
Interleukin-12 and STAT4 also appear to be linked to IBD in 
humans. There are a number of IBD-associated SNPs in the IL12B 
gene in Caucasian populations that correlate with enhanced dis-
ease (Figure 1; Table 2). STAT4 SNPs are associated with UC, but 
not CD, in some populations (51, 59, 85), suggesting a restricted 
role for these polymorphisms in human disease. More strikingly, 
STAT4 isoform ratios appear to be a better predictor of disease 
in IBD patients. STAT4 is produced as two distinct isoforms 
(α and β), where the STAT4β variant lacks 44 amino acids at 
the C-terminal end of the protein spanning the transactivation 
domain. Patients with UC or CD have elevated STAT4β:STAT4α 
ratios as compared to non-IBD controls and this ratio is norma-
lized after steroid treatment (86). In both murine models of colitis 
and experimental autoimmune encephalomyelitis, CD4 T  cells 
only expressing the STAT4β isoform drive exacerbated disease 
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as compared to cells expressing the STAT4α isoform (87, 88). In 
the murine IBD model, STAT4α- and STAT4β-expressing cells 
had a similar capacity to produce IFN-γ and IL-17, but STAT4β 
preferentially drove expression of TNF and GM-CSF that have 
been also described to play a role in IBD severity (25, 88). Again, 
these data indicate that while STAT4 in CD4 T  cells is critical 
for development of IBD, it might do so independently of IFN-γ.
Th17 CeLLS
The traditional Th1/Th2 paradigm of CD and UC was challenged 
with the discovery of a unique subset of IL-17-producing, termed 
Th17 cells (89). Th17 cells play an important role in maintaining 
commensal populations at important barrier sites (i.e., skin and 
gut), but when triggered in settings of autoimmunity can often 
exacerbate disease (89). The Th17 differentiation program is 
driven primarily by IL-6 and TGF-β (90) and further stabilized 
by signals from accessory cytokines including IL-23 and IL-1β 
(Figure 1) (91, 92). Interestingly, Th17 differentiation is inhibited 
by cytokines produced by other Th lineages including IFN-γ, 
IL-4, and IL-2 (93, 94). As IL-6 induces STAT3 phosphorylation, 
STAT3 and other downstream TFs, retinoic-acid-receptor-related 
orphan receptor (ROR) gamma and ROR alpha, are critical for 
Th17 differentiation in vitro and in vivo (95, 96). After differentia-
tion, Th17 cells primarily express IL-17A and IL-17F; however, 
these cells can also co-produce signature cytokines from other Th 
cell lineages in particular settings of autoimmune inflammation 
(i.e., IFN-γ: Th1, IL-22: Th22, IL-9: Th9).
Th17-Associated Cytokines
Interleukin-17
Th17 cells are largely defined by their capacity to produce IL-17 
(IL-17A and/or IL-17F) in settings of inflammation. IL-17 signals 
through a heterodimeric receptor (IL-17RA and IL-17RC) that is 
expressed on many non-hematopoietic cells including intestinal 
epithelial cells and on some activated T cells (97). Signaling through 
these receptors plays an important role in epithelial cell barrier 
function, and in the production of inflammatory chemokines and 
cytokines by target cells. In Th cells, IL-17 can also dampen the 
production of IFN-γ thereby possibly enhancing the stability of 
the Th17 phenotype by limiting Th1 differentiation (98).
Interleukin-17A protein in the serum and IL-17-producing Th 
cells in the gut-draining lymph nodes were elevated in patients 
with CD, but not UC, over non-IBD patients (99). In addition, 
the numbers of IL-17+ cells in the intestines of patients with active 
CD and UC were also elevated as compared to healthy controls 
and patients with inactive CD or UC (100). While IL-17A block-
ade is successful in diminishing disease in patients with plaque 
psoriasis and ankylosing spondylitis, treatment of CD patients 
with IL-17A-blocking antibodies surprisingly enhanced disease 
severity resulting in a premature end to these clinical trials 
(101, 102). These adverse effect studies were substantiated in mice 
where IL-17 blockade in a DSS model of colitis exacerbated dis-
ease symptoms as well as immune cell infiltration into the mucosa 
(103). This result was recapitulated in IL-17-deficient mice treated 
with DSS (104). Furthermore, transfer of IL-17A- or IL-17RA-
deficient Th cells into RAG recipient mice lead to an enhanced 
colitis-like wasting disease (98). Interestingly, IL-17R-deficient 
and IL-17R-Ig fusion protein-treated mice were protected from 
disease in TNBS model of UC, suggesting that the protective role 
of IL-17 may depend on the particular model of colitis used (30).
One explanation for the enhanced disease observed in anti- 
IL-17A-treated or IL-17A-deficient mice may be compensatory 
effects of other Th subsets or inflammatory cytokines. Indeed, 
O’Connor et al. (98) observed increased intestinal Ifng mRNA and 
increased Th1 polarization in the absence of IL-17A. Furthermore, 
addition of IL-17A to developing Th1 cells in culture suppressed 
IFN-γ production, suggesting that IL-17A limits Th1 differen-
tiation and Th1-mediated immunopathology. Unfortunately, the 
authors did not neutralize IFN-γ in these mouse experiments to 
determine if elevated IFN-γ in mice that had received IL-17A-
deficient Th cells was the cause of exacerbated disease. However, 
in Abcb1a-deficient mice that also develop enhanced colitis after 
Helicobacter infection and IL-17RA blockade, co-blockade of 
IFN-γ did not decrease disease severity (42), suggesting that 
increased IFN-γ may not be causative for the enhanced disease 
observed in the absence of IL-17. Leppkes et al. (105) demons-
trated a different type of immune compensation in the absence 
of IL-17A. This study observed striking increases in IL-17F after 
adoptive transfer of IL-17A-deficient cells into RAG-deficient 
hosts. Interestingly, antibody blockade of IL-17F in mice that 
had received IL-17A-deficient Th cells ablated disease. Similarly, 
Wedebye Schmidt et al. (106) also found that antibody-mediated 
blockade of either IL-17A or IL-17F alone was insufficient to 
reduce disease severity, whereas blockade of both IL-17A and 
IL-17F completely abrogated disease. These studies highlight the 
compensatory nature of the intestinal immune response during 
IBD and indicate that multiple Th cell types and cytokines likely 
work in concert to promote autoimmunity in this setting.
Another theory of why the absence of IL-17A enhances 
intestinal inflammation lies within its ability to regulate epithelial 
barrier function and gut homeostasis. Maxwell et al. (42) observed 
increased gut permeability in the Abdcb1a-deficient colitis model 
when IL-17RA signaling was abrogated via blocking antibodies as 
compared to control mice. This was further substantiated in a DSS 
model of colitis where antibody-mediated blockade of IL-17 also 
resulted in enhanced “leakiness” of the intestinal epithelial barrier 
(107). In both cases, the increase in permeability correlated with 
changes in epithelial tight junction gene expression and changes in 
occludin positioning within the damaged epithelial layer (42, 107). 
Interestingly, Maxwell et al. (42) demonstrated that IL-17 signaling 
was also critical for production of anti-microbial peptides (AMPs) 
that may influence bacterial populations within the intestines dur-
ing colitis. Song et al. (104) also showed that IL-17, in concert with 
fibroblast growth factor 2, regulated both epithelial barrier function 
and bacterial homeostasis in the gut. As a whole, these data indicate 
that although IL-17 has bona fide inflammatory properties, the 
barrier maintenance and microbial “grooming” function of IL-17 
is likely dominant and is crucial for protection against intestinal 
barrier breach and enhanced inflammation during colitis.
Interleukin-23
Interleukin-23 is composed of the IL-12p40 and IL-23p19 subu-
nits and is produced primarily by DCs and monocytes in IBD 
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(108, 109). IL-23 signals through the IL-23 receptor (IL-23R) 
which is induced by TGF-β, IL-6, and STAT3 signaling on 
activated T cells (110, 111). IL-23 distinctly enhances Th17 dif-
ferentiation in vitro and lineage commitment in vivo (112, 113). 
Furthermore, IL-23 levels are elevated in intestinal biopsies taken 
from patients with IBD (109) and SNPs in the IL23R locus have 
been associated with increased risk for IBD (Table 2) (79, 114).
Interleukin-23 is also elevated in mice with colitis and largely 
appears to be required for disease progression. Interestingly, IL-23 
plays an important role in both innate and adaptive immune-
driven disease. Hue et al. (39) demonstrated that treatment with 
neutralizing antibodies to IL-23p19 blocked the development 
of innate-driven infectious colitis in a 129SvEvRAG−/− mice. 
Furthermore, adaptive immune-driven colitis in an adoptive 
transfer RAG model of disease was abolished when CD45RBhi 
cells were transferred into mice lacking both IL-12p40 and 
IL-23p19, but not in mice lacking individual cytokines (39). These 
findings were confirmed in similar models where either IL-23R-
deficient donor cells (115) were transferred or IL-23 signaling 
was blocked with neutralizing antibodies (116). There was also 
a reduction in disease in IL-23p19-deficient mice treated with 
anti-CD40 agonist antibody as compared to anti-CD40-treated 
WT controls (Table 1) (36). In essentially all situations, reduced 
disease in these animals correlated with a reduction in IL-17+ 
CD4 T cells, particularly those that co-produce IFN-γ, suggest-
ing that these IL-17+/IFN-γ+ cells may be the major inducers of 
disease. Interestingly, both Ahern et al. (115) and Uhlig et al. (36) 
observed that while IL-23p19-deficient mice lacked intestinal 
pathology there was very little difference in the weight loss that 
is often associated with murine models of colitis. By contrast, 
IL-12p40-deficient mice exhibited reduced weight loss, but 
minimal reductions in intestinal pathology (36), suggesting that 
weight loss and intestinal pathology are controlled by divergent 
mechanisms.
Similar to IL-17, IL-23 is not always pathogenic, and in some 
cases, can have a protective role. Becker et al. (37) demonstrated 
in TNBS and DSS models of colitis that IL-23p19-deficient mice 
were much more susceptible to developing colitis as compared 
to their WT counterparts. This phenomenon was also observed 
in a model of infectious colitis, using C. rodentium, where 
antibody-mediated blockade of IL-23 or IL-23-deficiency exac-
erbated disease and enhanced mortality compared to controls 
(117). Both Aychek et  al. (117) and Becker et  al. (37) noted 
increased IFN-γ in the absence of IL-23 and enhanced disease 
could be ameliorated by blockade of IL-12 or IFN-γ. This is 
consistent with several reports noted above where lack of IL-17 
may result in enhanced Th1 responses and suggests a delicate 
balance in mechanisms that control development of intestinal 
inflammation.
Th17-Associated TFs
Signal Transducer and Activator of Transcription 3
STAT3 is activated via phosphorylation by kinases associated 
with the IL-6 and IL-21 receptor and is critical for in vitro and 
in  vivo differentiation of Th17  cells (96, 118). In IBD patients, 
there is an increase in both total STAT3 protein as well as phos-
phorylated STAT3 in the inflamed colon over non-IBD controls 
which correlated with disease severity (119, 120). There is also a 
STAT3 SNP associated with enhanced IBD susceptibility or dis-
ease severity in different populations, further implicating a role 
for STAT3 in both CD and UC (Figure 1; Table 2) (67, 121, 122). 
In line with these observations in humans, STAT3 signaling also 
plays a role in a mouse model of IBD. In a RAG adoptive transfer 
model of IBD, Durant et  al. (40) demonstrated that STAT3-
deficient CD45RBhi CD4 T cells were unable to differentiate into 
IL-17-producing cells and were unable to initiate inflammation 
in the intestines. Interestingly, lack of STAT3 in CD4 T cells had 
little effect on their capacity to produce IFN-γ, but significantly 
enhanced the frequency of these cells that became FOXP3+ 
T regulatory cells. STAT3-deficient CD4 T cells also lacked the 
ability to proliferate or survive in the lymphopenic environment 
present in RAG-deficient hosts. The authors further demonstrated 
via CHIP-seq analysis that STAT3 binds and promotes epigenetic 
remodeling of both Th17- and anti-apoptotic/survival-associated 
genes suggesting a complex role for T cell-intrinsic STAT3 in the 
progression of colitis.
SMADS
TGF-β binding to its receptor triggers activation and phospho-
rylation of SMAD proteins that translocate to the nucleus and 
influence transcription of a variety of genes involved in tumor 
metastasis and T helper cell differentiation. In T  cells, TGF-β 
induces SMADs 2 and 3 that form a complex with SMAD4 and 
activate transcription of a number of genes including FOXP3 and 
RORγt (123). Furthermore, SMAD-induced TGF-β signaling also 
results in increased expression of SMAD7 that acts as an inhibitor 
of TGF-β-induced signaling pathway (124).
Although TGF-β is critical in the differentiation of Th17 cells, 
each SMAD protein has a unique and sometimes antagonizing 
role in this process. SMAD2 promotes Th17 differentiation 
in vitro by enhancing IL-6R expression or by physically interact-
ing with the Th17-associated TF RORγt (41, 125). Furthermore, 
SMAD2-deficient CD4 T cells were unable to initiate colitis in 
a RAG adoptive transfer model and in a C. rodentium model of 
infectious colitis (Table 1) (41). By contrast, SMAD3-deficiency 
resulted in enhanced Th17 differentiation in  vivo (125) and 
SMAD4-deficiency had little effect on Th17 differentiation (96). 
However, more recent reports indicate that SMAD4 degradation 
might play an important role in Th17 differentiation. Zhang et al. 
(126, 127) demonstrated that SMAD4-deficient cells produced 
IL-17 in the absence of TGF-β in culture, an over-looked point 
in the previous study, and ectopic SMAD4 expression suppressed 
Th17 differentiation. Although SMADs 2, 3, and 4 have been 
proposed to work together to drive transcription, it is clear from 
these reports that each SMAD protein has a unique role in Th17 
differentiation.
SMAD7 expression is increased in lesional tissue isolated from 
patients with UC and CD, whereas phosphorylation of SMADs 
2 and 3 is reduced as compared to non-IBD controls (128), sug-
gesting a dominant role for SMAD7 in IBD. Blockade of SMAD7 
activity with an anti-sense oligonucleotide enhanced SMAD2 
activation and reduced inflammatory cytokine production in 
intestinal explants (128) and severity of colitis in mice sensi-
tized and treated with TNBS or oxazolone (29). Furthermore, 
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SMAD7-overexpressing T cells enhanced development of colitis 
in a RAG adoptive transfer model of colitis even in the presence 
of co-transferred T regulatory cells (129). Interestingly, SMAD7 
transgenic CD4+ T cells isolated from the intestines of these mice 
are not enriched for IL-17-producing cells, but instead have more 
IFN-γ-producing Th1 cells and have a lesser capacity to express 
FOXP3. These data are consistent with previous reports that 
demonstrated that TGF-β signaling in T regulatory cells induced 
FOXP3 which in turn limits SMAD7 expression (124). As a 
whole, these data indicate that an imbalance in T cell-intrinsic 
SMAD signaling does not promote Th17 differentiation in vivo, 
but rather enhances the ability of T cells to avoid Treg-mediated 
suppression.
RORγt
An immune-specific isoform of retinoic acid receptor-related 
orphan nuclear receptor gamma (RORγt), a type of nuclear 
hormone receptor (NHR), is critical for the differentiation of 
Th17 cells (95). RORγt is induced by both IL-6/STAT3 and in 
some cases TGF-β, two cytokines that drive Th17 differentiation 
(130). Currently, there has been no identified IBD-associated 
RORC SNPs suggesting that while it is critical for Th17 differen-
tiation, variations in this gene are not associated with enhanced 
disease.
Nuclear hormone receptors, like RORγt, are prime candidates 
for therapeutic intervention based on their mechanism of action 
where binding of a particular ligand controls their transcriptional 
activity. Natural ligands for RORγt have been recently identified 
as being a cholesterol biosynthetic intermediates (CBIs) and dele-
tion of enzymes that generate these CBIs appear to be involved 
in Th17 differentiation (131). There has been a great deal of 
interest in generation of small molecule inhibitors that would 
be able to block or displace binding of natural RORγt ligands to 
therapeutically inhibit Th17 responses during IBD. Withers et al. 
(132) demonstrated that therapeutic delivery of an oral-available 
Rorγt inhibitor (GSK805) was able to significantly reduce disease 
in a number of murine IBD models. Interestingly, GSK805 treat-
ment was more effective in treating disease that IL-17 blockade 
or deficiency and was not marked by compensatory increases 
in IFN-γ production as observed in studies mentioned above. 
These data suggest that either RORγt small molecule inhibitors 
target additional RORγt-expressing cells types that contribute to 
inflammation (i.e., ILC3s) or inhibit other Th17-associated func-
tions besides IL-17 production.
Th22 CeLLS
Th22 cells are characterized by their production of IL-22, but 
not IFN-γ or IL-17. Differentiation of Th22 cells occurs in the 
presence of IL-6, TNF-α, and IL-1β, and suppressed by TGF-β 
(Figure 1) (133, 134). Similar to Th17 cells, IL-21 also can enhance 
the differentiation of IL-22-producing T  cells (135). Although 
Th22 cells do not produce IFN-γ, they express high levels of T-bet 
that is critical for their differentiation (136). Furthermore, while 
expression of the aryl hydrocarbon receptor (AhR) TFs is low in 
Th22 cells as compared to Th17 cells, it is also critical for IL-22 
production from CD4 T cells (133, 136).
Th22-Associated Cytokines
Interleukin-22
Interleukin-22 is a member of the IL-10 family of cytokines and 
binds to IL-22R which is complex of IL-22R1 and IL-10R2 that sig-
nals primarily through STAT3 (137). IL-22 is elevated in both mice 
and humans with IBD (138, 139) and is known to have a protective 
effect against gut inflammation, tissue damage, and bacterial infec-
tion (136, 140–142). IL-22 producing Th cells were significantly 
reduced in inflamed tissues from UC patients and were replaced by 
IL-17-producing Th17 cells, suggesting that the balance of inflam-
matory and anti-inflammatory cells is disrupted during IBD.
In IBD, IL-22 ameliorated intestinal inflammation in a STAT3-
dependent manner that correlated with enhanced mucus produc-
tion by colonic epithelial cells (143). Mice deficient in IL-22 are 
susceptible to C. rodentium infection (136) and mice that lack 
STAT3 specifically in T cells exhibited enhanced susceptibility to 
infectious colitis during C. rodentium infection that was rescued 
by intestinal overexpression of IL-22 (144). Furthermore, adoptive 
transfer of Th cells cultured under Th22 conditions was sufficient 
to protect from C. rodentium infectious colitis (136). In both a 
DSS and RAG adoptive transfer model of colitis, IL-22-deficient 
mice or mice receiving IL-22-deficient Th cells exhibited enhanced 
weight loss and colon inflammation as compared to controls indi-
cating that IL-22 has a protective role in multiple models of murine 
colitis (145, 146). Together, these data suggest that Th22 cells are a 
relevant protective source of IL-22 during intestinal inflammation.
Interleukin-22 mediates its protective properties by inducing 
production of mucus and AMPs that have direct anti-microbial 
activity (141, 147). In addition, injection of IL-22 into mice 
induced the expression of LPS binding protein by hepatic cells 
thereby increasing the capacity to neutralize systemic LPS and 
reduce inflammation (138).
IL-22 Binding Protein (IL-22BP)
IL-22 binding protein exists as soluble inhibitory receptor and it is 
expressed at high levels in the PP and colon by DCs in the steady 
state and by CD4+ T cells during inflammation (146, 148–150). 
IL-22BP has higher affinity than IL-22R1 and competes for 
IL-22 binding with the cell-associated receptor, and interferes 
with the protective role of IL-22. Both UC and CD patients 
exhibit increased IL-22BP expression and IL-22BP+ cells in 
inflamed intestinal tissue as compared to healthy controls (149). 
Importantly, transfer of IL-22BP-deficient Th cells into either 
IL-22BP-sufficient or -deficient RAG mice resulted in less disease 
as compared to mice receiving WT Th cells, indicating that Th 
cell-derived IL-22BP was the biologically dominant source for 
pathogenic IL-22BP production during IBD (149). In future stud-
ies, it will be important to determine what Th cells are producing 
IL-22BP (i.e., Th1 and Th17) or if these cells are a unique Th 
subset. Furthermore, the factors that result in IL-22BP produc-
tion by Th cells is unknown. Understanding of this pathway will 
have clear implications for treatment of IBD.
Th22-Associated TFs
Aryl Hydrocarbon Receptor
STAT3 signaling and T-bet are required for the differentiation of 
Th22 cells (136) and the role of these factors in IBD have been 
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discussed above in terms of Th17 and Th1 differentiation, respec-
tively. Although Th22 cells do not express elevated levels of AhR as 
compared to Th17 cells, it is critical for their differentiation (136). 
As Th22 cells are associated with protection against intestinal dis-
ease, it is not surprising that AhR is also associated with protection 
from IBD. Patients with IBD exhibit significantly higher IL-22 and 
AhR expression as compared to healthy individuals (151), pre-
sumably to counteract enhanced inflammation within the tissue. 
In mice, transfer of AhR-deficient Th cells in a RAG model of coli-
tis induced more severe disease as compared to mice that received 
WT Th cells (135). In a murine TNBS colitis model, an AhR 
antagonist induced more severe colitis by suppressing synthesis 
of IL-22. By contrast, treatment of AhR agonist 6-formylindolo 
(3, 2-b)carbazole (FICZ), a tryptophan derivative, reversed relaps-
ing TNBS and DSS-induced colitis (151). Mechanistically, tryp-
tophan metabolites can alter the intestinal microbiota in favor 
of microbes that induce AhR production and AhR-dependent 
IL-22 transcription (152). As a whole, these data indicate that 
AhR expression in Th cells is required for IL-22 production and 
protection from IBD.
Th2 CeLLS
Th2 cells classically function to provide anti-parasite immunity, 
but are also known to be effector cells in asthma and differenti-
ate in response to IL-4 (153). IL-4 signaling in Th2 cells leads 
to activation of the receptor-associated signaling molecule 
STAT6 and downstream induction of the Th2 defining TF 
GATA3 (Figure 1) (153). GATA3 is able to further polarize the 
differentiation of Th2 cells through a positive autoactivation 
pathway (154) and can also convert committed Th1 cells can 
to Th2 cells when ectopically expressed (155). While Th1 cells 
are indicative of CD, Th2 or Th2-like cells are more associated 
with UC. This Th1/Th2 paradigm, although controversial, has 
been recently supported by the development of an equation 
that can predict CD vs. UC based on cell populations with 83% 
accuracy (156).
Th2-Associated Cytokines
Interleukin-4
The role of IL-4 in perpetuating IBD is controversial. T  cells 
isolated from UC biopsies do not exhibit significant production 
of IL-4, which has shown to be vital in the differentiation of Th2 
cells and their defining cytokine (157). Similarly, IL4 mRNA 
expression in intestinal mucosa in both CD and UC patients was 
undetectable (158). IL-4, in combination with IL-10 (another 
cytokine enriched in Th2 cells), has also been shown to syner-
gistically inhibit the pro-inflammatory cytokines TNF-alpha and 
IL-1β that are associated with IBD (159). Furthermore, SNPs 
present in the IL-4 gene are overrepresented in UC patients and 
are presumably loss of function mutations, suggesting a possible 
regulatory role of these cytokines in IBD patients (Figure  1; 
Table 2) (69). However, anti-IL-4 treatment of mice undergoing 
oxazolone-induced colitis or TCRα−/− adoptive transfer model 
prevented the majority of disease (31, 43, 160). These data indi-
cate that IL-4 may have anti- or pro-inflammatory roles based on 
the particular type of IBD or mouse model used.
Interleukin-5
Stimulated lamina propria (LP) T cells isolated from colonic biop-
sies from UC patients had increased expression of IL-5 compared 
to CD and control patients (161). An assessment of cytokine tran-
scripts in UC and CD patients found IL-5, IL-13, IL-15, and IL-33 
mRNA levels to be increased in UC patients (162). Although IL-5 
is produced in these tissues, its exact contribution to UC is still 
unclear. IL-5 is a potent inducer of eosinophils from the bone 
marrow and there is some evidence that elevated IL-5 levels in 
UC promotes the recruitment of eosinophils into the inflamed 
intestine (163, 164). The role of these eosinophils in UC, however, 
remains unclear.
Interleukin-13
Similarly, LP mononuclear cells from UC produced much larger 
amounts of IL-13 than CD or control patients (33). However, the 
source of IL-13 was not always T cell derived. In human studies, 
both LP Th cells and invariant natural killer T cells accounted for 
the majority of the IL-13 production (161, 165). IL-13 is also pro-
duced in mice by intestinal ILCs (166, 167). Interestingly, IL-13 
signaling through the once thought “decoy” IL-13Rα2 receptor 
induces TGF-β and fibrosis of intestinal tissue in a chronic model 
of TNBS colitis (26, 27). Given the apparent importance of IL-13 
in both human IBD and murine model studies, IL-13-specific 
antibodies (anrukinzumab and tralokinumab) have been trialed 
as therapy for UC patients. Unfortunately, anrukinzumab did 
not show significant therapeutic effect in UC patients with active 
disease (168). Tralokinumab showed some improved clinical 
remission rates and mucosal healing, but did not have significant 
clinical response when compared to placebo, which may indicate 
limited therapeutic benefit (169).
Th2-Associated TFs
Signal Transducer and Activator of Transcription 6
STAT6 is activated by the cytokines IL-4 and IL-13 and binds a 
number of IL-4-responsive promoters (170). Activated STAT6, 
as measured by phosphorylation, was also enhanced in intestinal 
tissues take from UC patients and correlated with disease severity 
(171). There is also one reported SNP in the STAT6 gene that 
is associated with CD (Figure  1; Table  2) (68). In models of 
UC (e.g., DSS and oxazolone-induced UC), STAT6 can play an 
important role in IBD pathogenesis through changes in inducible 
NO synthase or tight junction proteins and Th2 cytokine produc-
tion (20, 172). However, STAT6 was found to be dispensable in a 
TCRα−/− colitis model (173).
GATA3
STAT6 binds the promoter and activates transcription of 
GATA3; GATA3 can subsequently induce its own expression 
and inhibit Th1 production. Thus, GATA3 is a lineage-defining 
factor for Th2 cells. GATA3 was expressed at higher levels in 
colonic tissue from UC patients compared to ileal CD patients 
and correlated with disease severity. Furthermore, UC patients 
had an increased number of mucosal CD4+/GATA+ cells (35). 
This has also been shown in pediatric UC patients, those with 
active disease had increased expression of mucosal GATA3 
compared to age-matched controls (174). In a murine models 
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of UC (DSS and oxazolone-induced UC), overexpression of 
GATA3 accelerates acute colitis in contrast to overexpression of 
T-bet or RORγt (21, 35). Furthermore, T cell-specific GATA3-
deficient mice were resistant to oxazolone-induced disease and 
treatment with hgd40 DNAzyme that cleaves GATA3 mRNA 
also exhibit a significant decrease in disease severity (35). 
Currently, SB012, which contains hgd40, is being investigated 
for use in UC patients (https://www.clinicaltrials.gov/show/
NCT02129439).
Others
c-MAF is a TF that is associated with Th2 and Th17 differentia-
tion and aids in both IL-4 and IL-17 production (175, 176). CD 
and UC patients have increased numbers of c-MAF+ T cells in the 
inflamed intestine. Interestingly, c-MAF+ cells were also T-bet+, 
a Th1-associated factor, suggesting that these cells may have a 
Th1-like phenotype (177). Furthermore, c-MAF overexpressing 
naïve CD4 T cells were unable to induce colitis as compared to 
WT controls. However, c-MAF overexpression within memory/
effector CD4 T  cells, normally containing T  regulatory cells, 
augmented colitis when co-transferred with naïve Th cells (177). 
Deletion of c-MAF in T regulatory cells also limited their ability 
to produce the anti-inflammatory cytokine IL-10 and regulate 
microbiota-specific Th cells (178). These data indicate that there 
is a fine balance in c-MAF expression in T regulatory cells that 
controls their regulatory capacity.
The TF NFAT is also involved in Th2 differentiation and NFAT 
family member expression was enriched in the inflamed intestine 
during IBD (179). A gene controlling NFAT nuclear translocation 
was identified as a key IBD susceptibility gene in human IBD 
GWAS studies (180). Furthermore, genetic deletion of NFATc2 
results in reduced disease in an oxazolone model of murine colitis 
by modulating the ability of Th cells to produce IL-6, a cytokine 
normally associated with Th2 cells (181).
Th9 CeLLS
Interleukin-9 producing T  cells were initially thought to be a 
subset of the Th2 population. This changed after the finding that 
TGF-β, together with IL-4 reprogram Th2 cells to become Th9 
cells that secrete IL-9 and IL-10 and have a unique transcriptional 
profile (Figure 1) (182, 183). In these cells, IL-9 production is 
under the control of PU.1, STAT6, BATF, GATA3, and IRF4 (183, 
184). TGF-β, in particular, stimulates the production of TF PU.1, 
which in turn induces IL-9 expression (185).
Th9-Associated Cytokines
Interleukin-9
Recent studies both of CD and UC patients have shown IL-9 pro-
duction to be enhanced in these disease states and correlates with 
endoscopic Mayo scores (34). Further studies have also revealed 
that in UC patients, activated peripheral blood lymphocytes pro-
duced increased amounts of IL-9 (186). Clinically, patients with 
increased serum IL-9 levels have been shown to have a worsened 
prognosis (187) and higher levels of systemic IL-9 were also 
associated with cachexia and lower hemoglobin concentrations 
in IBD patients (188).
In mouse studies, mice with oxazolone-induced colitis 
exhibited increased IL-9 expression and IL-9-deficient mice were 
resistant to development of colitis (34). Interestingly, therapeuti-
cally targeting IL-9 with a neutralizing antibody in these studies 
also significantly reduced disease over controls, and this was also 
verified in a DSS model of UC (22). In a TNBS-induced colitis 
model, IL-9-deficient mice were also resistant to colitis devel-
opment and suggested that IL-9 may have a role in regulating 
intestinal barrier function (28). In additional studies using the 
RAG adoptive transfer model of colitis found that when IL-9-
producing T  cells were transferred into RAG 1-deficient mice, 
the mice exhibited increased degree of colitis (189). As compared 
to other cytokines that have model-dependent protective or 
pathogenic roles in IBD (i.e., IFN-γ and IL-17), IL-9 appears to 
have a consistent pathogenic role across disease models making 
it a potential druggable target in IBD.
Tofacitinib, one of the newest approved therapies for IBD, is 
a small molecule Janus kinase (JAK) inhibitor that has shown 
promising therapeutic potential in UC (190). The JAK family 
includes intracellular tyrosine kinases that activate STATs to 
control multiple cytokines including IL-9. However, IL-9 is one 
of the many cytokines that are inhibited; perhaps newer therapies 
with more targeted IL-9 activity may be beneficial in patients who 
have failed other forms of treatment.
Interleukin-10
Th9 cells also produce IL-10, which is classically known to be 
immunosuppressive (184). However, as above, experiments by 
Dardalhon et al. showed that transferring IL-9 and IL-10 double 
positive cells into RAG 1-deficient mice worsened colitis in these 
mice (189). However, IL-10 and its role in IBD has been studied 
extensively. IL-10-deficient mice irrefutably develop colitis 
spontaneously and pathologically resemble human IBD (191). 
The role of IL-10 in relation to Th9 cells, however, needs to be 
further elucidated.
Th9-Associated TFs
PU.1
PU.1 is required for Th9 development and is produced more 
in these cells compared to the other subsets (185). In Th9 cells, 
PU.1 binds to the Il9 promoter and alters histone acetylation 
(192). In human IBD, the number of PU.1+ Th cells is higher 
in mucosal biopsies of patients with active IBD (34). This was 
also shown using immunohistochemistry to assess the density of 
PU.1 expressing cells in both human UC and murine DSS colitis 
(22). Moreover, mice with PU.1-deficient T cells had diminished 
pathology in the oxazolone model (34).
Others
STAT6, GATA3, and SMAD proteins are also required for Th9 dif-
ferentiation and may be involved in Th9-mediated colitis. Indeed, 
IL-9 is significantly reduced in oxazolone-induced colitis when 
GATA3 is deficient in T cells (35). However, the role of STAT6 
and SMADs on IL-9 production in colitis has not been examined. 
IRF4 is also required for differentiation of Th2, Th9, and Th17 cells 
(193–195) and is required for inflammation in a RAG adoptive 
transfer model of colitis (196, 197). Therefore, a number of TFs 
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that play a role on other Th lineages can also impact Th9 function 
during intestinal inflammation.
OuTLOOK ON iBD THeRAPY
Over the last several decades, researchers have generated a 
tremendous amount of information regarding how the CD4+ 
Th response influences the outcome of IBD in both mice and 
humans. This has already led to the development of a number 
of biologics (i.e., anti-TNF) that are effective in causing at least 
temporary remission from disease. However, these therapies are 
only effective in causing endoscopic and microscopic remission 
in a subset of patients. In this review, we have highlighted a 
number of instances where depletion or deletion of particular 
Th-associated cytokines can have deleterious effects. In the 
majority of these instances, there are compensatory immune 
mechanisms that either render treatment ineffective or make 
disease considerably worse. Clearly, more work must be done to 
identify these compensatory mechanisms and be able to predict 
them in both murine models of disease and in human patients. 
Broad-scale successful treatments of IBD will likely require target-
ing multiple arms of the Th cell response to account for compen-
sating mechanisms that may be unique to each individual. These 
personalized treatments might include bi-specific antibodies or 
multiple biologics used in conjunction to account for predicted 
compensatory responses.
There are, however, some inherent drawbacks to this “multi-
faceted” approach. Targeting multiple immune mechanisms will 
likely occur at increased cost to the patient. CD treatment is 
already ~3× more expensive than UC therapy with ~64% of that 
cost being driven by anti-TNF therapy (198), a cost that will 
likely increase when multiple biologics are used. One approach 
to this problem is to utilize a broader pan-Th inhibitor that might 
target multiple cytokines that are produced by a number of Th 
subsets. As the majority of these cytokines signal through cytokine 
receptor-associated JAKs, JAK inhibitors are an attractive target 
for limiting autoimmune inflammation. The JAK inhibitor tofaci-
tinib has been approved for treatment of rheumatoid arthritis and 
has shown promise in phase 3 clinical trials in IBD (199). Beyond 
cost, targeting multiple arms of the immune system may also 
lead to increased susceptibility to infection or cancer. Although a 
number of Th-associated cytokines are involved in IBD pathogen-
esis, almost all of these have evolved for protection from infection 
and for regulating gut homeostasis and microbiota. Patients on 
anti-TNF therapy are more susceptible to a number of infections 
and development of particular types of tumors (200, 201). It is easy 
to imagine that combination of anti-TNF therapy with anti-IL-23 
or a JAK inhibitor would further increase susceptibility and thereby 
limit the efficacy or desirability of treatment. Ideally, future treat-
ments would target offender-only molecules that do not also play 
protective or homeostatic roles in the immune system. A recent 
study by van Unen et al. (202) used high parameter time of flight 
mass cytometry (CyTOF) to identify a number of novel immune 
cell populations that correlate with disease in IBD patients. This 
type of data will be instrumental in identifying possible “offender-
only” immune cell populations that may be targeted therapeuti-
cally without hampering normal host immune responses.
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